ASH 2020 | What’s to come for the MMRF in 2021?
Daniel Auclair
• 15 Dec 2020
Daniel AuClair, PhD, Multiple Myeloma Research Foundation (MMRF), Norwalk, CT, shares the upcoming plans of the MMRF. 2021 will focus on targeting unmet needs in myeloma, including high-risk smoldering myeloma, rapid relapse, and patients refractory to anti-CD38 and BCMA therapies. Immune profiling will also be a focus point, with MMRF launching trials such as CureCloud, a direct-to-patient initiative for genomic profiling and disease monitoring, and MyDRUG to develop personalized treatment regimens. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
